The estimated Net Worth of Sheldon L Bloch is at least $1.79 millió dollars as of 27 November 2006. Sheldon Bloch owns over 2,639 units of AMAG Pharmaceuticals stock worth over $1,744,450 and over the last 18 years Sheldon sold AMAG stock worth over $40,584.
Sheldon has made over 3 trades of the AMAG Pharmaceuticals stock since 2006, according to the Form 4 filled with the SEC. Most recently Sheldon exercised 2,639 units of AMAG stock worth $108,621 on 27 November 2006.
The largest trade Sheldon's ever made was exercising 2,639 units of AMAG Pharmaceuticals stock on 27 November 2006 worth over $108,621. On average, Sheldon trades about 1,460 units every 19 days since 2006. As of 27 November 2006 Sheldon still owns at least 69,778 units of AMAG Pharmaceuticals stock.
You can see the complete history of Sheldon Bloch stock trades at the bottom of the page.
Sheldon's mailing address filed with the SEC is C/O ADVANCED MAGNETICS, INC., 125 CAMBRIDGEPARK DRIVE, 6TH FLOOR, CAMBRIDGE, MA, 02140.
Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over $162,079,471 worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth $65,172,892 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Partners Gp, L.L.C.... és Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of $2,148,850. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth $59,572,300.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
AMAG Pharmaceuticals executives and other stock owners filed with the SEC include: